Proteotech Inc.

Cognitive Clarity Inc.

Protamed, Inc.

Qubai Hu

Alan D Snow

Judy Cam

Thomas P Lake

Joel Cummings

F Michael Hudson

Marisa C Yadon

Luke A Esposito

Gerardo M Castillo

Virginia J Sanders

Beth P Nguyen

Franz F Hefti

Geoffrey Golding

Seok-Rye Choi

Ximin Li

Esposito A Luke

Composition and methods for treating brain 'plaques' and 'tangles' in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncariaextract and an oolong tea extract.

Compositions and methods for the treatment of plaques and tangles in humans and animals

Methods of treating the formation, deposition, accumulation, or persistence of beta-amyloid containing plaques and tau protein containing tangles including the step of treating the plaques or tangles with an effective amount of a composition comprising anextract and an oolong tea extract. Compositions containing anextract in combination with an oolong tea extract.

Composition and methods for treating brain 'plaques' and 'tangles' in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprisingextract and an oolong tea extract.

Compositions and methods for the treatment of 'plaques and tangles' in humans and animals

This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

Compounds and compositions for use a modulators of tau aggregation and alleviation of tauopathies

Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

Compounds for the treatment of neurodegenerative diseases

Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

The identification of novel Syndecan-2 splice variants and their use in the diagnosis and therapeutic intervention of Alzheimer's disease and other amyloid diseases. In addition the use of new animal models expressing or devoid of syndecan-2 splice variants to effectively screen and identify potential therapeutic compounds for Alzheimer's disease.

Proteoglycan splice variants as therapeutics and diagnostics for amyloid diseases

Compounds and compositions for use as modulators of tau aggregation and alleviation of tauopathies

This invention relates to bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable salts and their use in the modulation of Sirtuin 1 (Sirt1) and there use in neuroprotection for subject suffering from neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, including Parkinson's plus diseases such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and dementia with Lewy bodies, and in the manufacture of medicaments for such Sirt1 modulation and neuroprotection.

Sirtuin 1 and the treatment of neurodegenerative diseases

Use of a peptide or pharmaceutical composition comprising Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D amino acid for the reduction of beta-amyloid protein, modulating APP processing, modulating activity of APP secretases, treatment of beta-amyloid protein diseases and the treatment of Alzheimer's disease.

Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein disorders

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, use in the reduction of A&#x3b2; peptide in vivo, use in modulating APP processing, and use in modulating the activity of APP secretase.

Growing community of inventors

Kirkland, WA, United States of America

Qubai Hu